Schedule an Appointment
PlantForm Corporation

PlantForm Corporation

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

PlantForm Corporation

Location: Toronto, Ontario

Sector: Life Science

.

Add to Shortlist
Express Interest

PlantForm Corporation is a privately-held Canadian biopharmaceutical company, commercializing a plant-based manufacturing platform, vivoXPRESS®, for the low-cost production of high-value therapeutic drugs. Their pipeline includes biosimilar drugs with a focus on international markets including China, Europe, India, Latin America, MENA as well as major North American and European markets. The company is also developing innovator biologics for niche infectious disease and countermeasures-to-bioterrorism markets. Their pipeline is funded through equity, government grants and contracts from non-profit organizations, such as the Bill & Melinda Gates Foundation.

Business Documents

MG cp Summary

Patented production system (vivoXPRESS®) – The plant based production system produces high quality drugs at very low cost.

 

Unique glycosylation of drugs – Protein and antibody molecules often have carbohydrates (sugars) decorating the surface. PlantForm can create unique structures increasing the efficacy and reducing the dose such protein and antibody drugs.

 

Experienced management team – Veterans in the biotechnology industry having the experience to move the high-value PlantForm investment proposition forward.

PlantForm Corporation is a privately-held Canadian biopharmaceutical company, commercializing a plant-based manufacturing platform, vivoXPRESS®, for the low-cost production of high-value therapeutic drugs. Their pipeline includes biosimilar drugs with a focus on international markets including China, Europe, India, Latin America, MENA as well as major North American and European markets. The company is also developing innovator biologics for niche infectious disease and countermeasures-to-bioterrorism markets. Their pipeline is funded through equity, government grants and contracts from non-profit organizations, such as the Bill & Melinda Gates Foundation.

Don Stewart, CEO

Dr. Don Stewart, an entrepreneur and scientist, is a founder of PlantForm and assumes the roles of President and Chief Executive Officer.  Dr. Stewart brings 30 years’ management experience in the biotechnology industry to this role.  Dr. Stewart has founded and developed companies in the field of biotechnology and in real estate.

 

Ron Hosking, CFO

Mr. Ron Hosking, an experienced financial manager and chartered accountant, is a founder of PlantForm Corporation. Mr. Hosking brings 35 years of experience, providing strong leadership, sound business management and clear strategic financial direction to growing businesses in the life sciences industry.

 

David Cayea, COO

Mr. David Cayea is an entrepreneur who has successfully launched private-sector companies in multiple industries over the last 20 years.  Mr. Cayea joined PlantForm in 2011 as Director of International Relations & Business Development, responsible for advancing the Companies strategic growth strategy by developing and fostering global partnerships. More recently Mr Cayea was appointed to the expanded role of COO of PlantForm.


CardioComm Solutions, Inc.

CardioComm Solutions, Inc.

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

CardioComm Solutions, Inc.

Location: Toronto, Ontario 1
Sector: Life Science 1
1
Add to Shortlist
Express Interest

CardioComm Solutions, Inc. is a medical software company that specializes in developing solutions for mobile cardiac monitoring for the sports, medical and wellness markets. Specifically, they’re developing connectivity and integration solutions for ECG monitoring from wearable and holdable sensors to enable mobile monitoring of consumers or patients through medially credentialed (FDA, CE, Health Canada) compliant software solutions sold globally.

Business Documents

MG cp Summary
  • Has secured the software and device clearances for OTC class II medical device sales in Canada and the USA.
  • Has developed a SMART Monitoring ECG reading service for all HeartCheck™ branded/compatible devices.
  • Can leverage its experience securing medical device clearances to help consumer health device manufacturers get their products cleared.
  • Will have access to many devices without the cost and responsibility of developing and manufacturing.
  • Will facilitate sales of the devices through the sale of its GEMS based software and the device manufactures will facilitate the sale of CardioComm’s software through the sale of their devices outside of North America.

CardioComm Solutions,  Inc. is a medical software company that specializes in developing solutions for mobile cardiac monitoring for the sports, medical and wellness markets. Specifically, they’re developing connectivity and integration solutions for ECG monitoring from wearable and holdable sensors to enable mobile monitoring of consumers or patients through medially credentialed (FDA, CE, Health Canada) compliant software solutions sold globally.

Robert E. Caines, Chairman of the Board

Mr. Caines, Managing Partner / Founding Partner at Paley Advisors, is a serial entrepreneur and mergers and acquisitions executive with over thirty years of business startup, growth and management experience.  He founded Paley Advisors in 2014.  From 2002 to 2014.  He served as one of three Managing Partners at Paley Dixon, Inc., the New York City-based buy-side intermediary and advisory firm, founded in 1979.  There, he and partners Sarah Cooke and Richard Paley grew Paley Dixon into one of the top five buy-side intermediaries and advisory firms of its size in the US and Canada.  Previous to Paley Dixon, he held senior-level sales and sales management positions at Hummingbird, BrightStar, NetEra and ADP.  Previous to ADP.  Mr Caines and partners founded Cable Channels, Inc., the cable television electronic program guide software firm.  He currently serves as President and Founding Partner of a customized B2C/B2B cross-border shipping solutions provider, to be launched in Q2 2016.  He also serves as Treasurer and member of the Board of Directors of Kensington House Owner’s Corporation.  Mr. Caines previously served as Treasurer and member of the Board of Directors of the Salmagundi Club, as Treasurer and member of the Board of Directors of the Ali Forney Center and as a member of the Advisory Board of the Peccadillo Theatre Company.  He received a Master of Business Administration degree from the Thunderbird School of Global Management and a Bachelor of Architecture degree from the College of Engineering at the University of Notre Dame.

 

William E. Smith, Board Member

Mr. Smith began his career as a systems engineer at IBM Canada where he was sent to Japan in 1972 to provide IMS manufacturing expertise to Toyota.  In 1990, Mr. Smith underwent rigorous TV training in San Francisco and was live on CNN, Good Morning America and various live TV talk shows in Silicon Valley. He was invited in 1990 to be a keynote speaker at PAC Bell’s annual corporate convention where he spoke on the future of Home Automation technology. He was a guest speaker at Seybold’s first “Digital World” conference in Beverley Hills in 1991 where he spoke on the future of the digital highway and first proposed the revolutionary digital highway to Pac Bell and an audience of Silicon Valley high tech personalities.  Mr. Smith proudly describes how this was globally reported in Wired Magazine. As the founder of CardioComm Solutions in 1989, he is most pleased with his nomination as Canadian Entrepreneur of the Year in 1995.  Later in 2000 as Microsoft EMEA Finance Industry Manager, he traveled extensively throughout EMEA and been guest speaker at a large number of external conventions including : Abtec 2001, First Arab eBanking Summit, April 2001, Dubai, UAE, The European IT Banking Forum 2000, November 2000, Milan, Italy , Bank Tech New Era, November 2000, Cairo, Egypt, EBank 2000. Sept 2000, Dubai , 17th Asian Bankers Association General Meeting. Sept 2000, Istanbul , Themen für IDC- Branchenkonferenz Banken 2000.  Feb 2000, Vienna, EE/MENA CEO Summit, Feb 2000 London, FinanceSector.com – Christiana Bank, March 2000 Oslo By 2001 .  He was completing 2 years at Microsoft as EMEA Finance Industry Manager for Microsoft Europe, Middle East and Africa.  He left Microsoft in May 2001 to take the position of COO with ICT, a startup company focused on Core Banking opportunities in Financial Services.  In February 2004, Mr. Smith was invited by Royal Roads University of Canada to a life changing event – teaching a two week pre-MBA boot-camp course to 55 mature learners in Tehran, Iran.  Mr.Smith has always made an effort to understand the cultural issues of international business.  His training includes Intensive Spanish – Instituto Cervantes, London – October 2001 Survival Arabic – London University, School of Oriental and African Studies – March 2003 .  He is delighted to have been invited back CardioComm Solutions, Inc. as Director and to offer his contributions to the development of CardioComm Solutions, Inc. into a world class global cardiology company. 1

 

Etienne Grima, Chief Executive Officer

Mr. Grima has over twenty-two years of experience in basic and clinical research administration, business development and strengthening corporate performance.  Recognized for a unique and multidisciplinary approach to overseeing operational performance and fiscal resources, Mr. Grima joined the Board of Directors of CardioComm Solutions, Inc. in December of 2006. In January of 2008 he was requested to serve as the company’s Chief Financial Officer and Corporate Secretary during a period of organizational restructuring.  In May of 2010 he accepted the position of Chief Executive Officer.  Mr. Grima has also held the position of Chief Operating Officer and Financial Officer for the Canadian Heart Research Centre (CHRC) since its start in 1996 and a similar role in MD Primer Inc. since 2004.  In all his roles, Mr. Grima continues to oversee operational and financial performance, contract and budget negotiations, finance reporting and the evaluation of strategic partnerships and long term growth opportunities. Prior to the CHRC, Mr. Grima managed the St. Michael’s Hospital (SMH) Health Sciences Research Centre in Toronto.  He guided SMH to become the fastest growing University of Toronto affiliated research center between 1994 and1997, acting as the signing officer on 350 externally funded clinical and basic research budgets, and overseeing the design, construction and maintenance of 27,000 square feet of clinical and basic research laboratories.  During his tenure, he developed a detailed understanding and methodology of the successful performance of clinical research within a hospital environment and became a member and Accredited Health Science Executive of the Canadian College of Health Service Executives.  His educational background was rooted in his persistent interest in biology and he completed his academic career with an emphasis on human physiology, toxicology and zoology graduating from University of Toronto with high distinction in 1984.  He completed his graduate studies in 1986 with a Masters degree from the Faculty of Medicine, Department of Physiology, Centre for Research in Neurodegenerative and served as a peer reviewer for research publications and grant applications. 1 1


Windsor Botanical Therapeutics Inc.

Windsor Botanical Therapeutics Inc.

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

Windsor Botanical Therapeutics Inc.

Location: Toronto, Ontario

Sector: Life Science

 

Add to Shortlist
Express Interest

Windsor Botanical Therapeutics Inc. is developing a botanical health product, extracted from the root of Taraxicum officinale, (dandelion) for sale as a complementary therapy for cancer. The extraction process was scaled up to Good Manufacturing Process (GMP) status and is currently being manufactured under GMP standards by Advanced Orthomolecular Research (AOR) of Calgary, AB. This complex extract has undergone preliminary analysis to identify key active components. WBTI intends to develop the material as a standardized botanical health product and, ultimately, an evidence based therapeutic. The product category, “Complementary Medicines for Cancer Therapy”, is estimated by Business Nutrition Journal to be a $1.1 billion market in the U.S.

Business Documents

MG cp Summary
  • If clinical testing results allow DRE-W to make cancer treatment claims, then DRE-W will stand out as a unique product in the natural health care product market – Currently available natural healthcare products can not make any claims regarding use as a cancer treatment.
  • Each batch of DRE-W produced by WBTI is quality controlled to ensure its ability to kill cancer cells. Studies conducted by WBTI provided the basis for a validated quantitative method of quality control- Studies conducted by WBTI showed that the effectiveness of homemade and commercially produced dandelion root extract vary widely or are non-existent.
  • Our research indicates that DRE-W is non-toxic: the Stage 1 Clinical trial will officially confirm this and the Stage 2 Trial should confirm that DRE-W improves patients’ well-being and reverses the progress of their disease Chemotherapy is toxic and can cause nausea, loss of appetite, loss of hair, discomfort, and a weakening of the body’s immune system.
  • WBTI owns a patent for the process to produce quality controlled DRE-W- Homemade and commercially available dandelion root extract either does not kill cancer cells or has no consistency in doing so. WBTI has spent the last 6 years researching and developing protocols to create effective DRE-W and only WBTI has the patent for its manufacturing process.

WBTI is developing a botanical health product, extracted from the root of Taraxicum officinale, (dandelion) for sale as a complementary therapy for cancer. The extraction process was scaled up to Good Manufacturing Process (GMP) status and is currently being manufactured under GMP standards by Advanced Orthomolecular Research (AOR) of Calgary, AB.  This complex extract has undergone preliminary analysis to identify key active components. WBTI intends to develop the material as a standardized botanical health product and, ultimately, an evidence based therapeutic. The product category, “Complementary Medicines for Cancer Therapy”, is estimated by Business Nutrition Journal to be a $1.1 billion market in the U.S.

Joseph Elliot, Chief Executive Officer, Director

 Dr. Elliot is founding President  & CEO of Windsor Botanical Therapeutics Inc. a developer and marketer of a breakthrough natural therapy for terminal cancer patients.

He is also Principal at Biopharm Management Inc. (BMI) a Toronto, Canada based firm providing short and long term management services to the biopharmaceutical industry. For the past 27 years Dr. Elliot has been a serial entrepreneur and former venture capitalist.

Dr. Elliot is a hands-on manager with skills and experience in all facets of the biopharmaceutical business including raising capital, financing, licensing, team building, drug development, manufacturing, regulatory affairs (FDA, Health Canada and BfArM).  He has broad experience pharmaceuticals, biologicals and vaccines in oncology and infectious diseases.

Through BMI, Dr. Elliot is currently Managing Director of ERC USA, the North American subsidiary of ERC Belgium, a break-through developer of therapeutic cancer vaccines.

In the past 15 years, Dr. Elliot has raised over $30 million for a number of companies in which he played a leading management role including the founding and growing several biotech companies. These include President & CEO of Receptor Therapeutics Inc., President & CEO of LymphoSign Inc., Vice President & General Manager Operations for MDS Proteomics Inc.; Chief Operating Officer for MDS Ocata Inc.; Interim Chief Operating Officer of Exogen Neurosciences Inc. He is the founding President and Chairman of PhageTech Inc. of Montreal, Quebec which had a successful IPO under the name Targanta Therapeutics Corporation. He was also initial CEO of Cytochroma Inc., (which was subsequently acquired by OPKO in 2013). He is also a past director of Nexia Biotechnologies Inc. of Montreal, Quebec, and BIOSTAR Inc. of Saskatoon, Saskatchewan.  From 1996 to 1999 he was a Vice President (Venture Capital) with MDS Capital Corp. specializing in early stage biotechnology investments.


ProMIS Neurosciences, Inc.

ProMIS Neurosciences, Inc.

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

ProMIS Neurosciences, Inc.

Location: Toronto, Ontario

Sector: Life Science

 

Add to Shortlist
Express Interest

Our mission is to discover and develop precision medicine therapeutics for disease modifying treatment of neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).

As its primary objective, the Company will focus on the discovery and development of specific therapeutics and companion diagnostics directed against the several strains of misfolded (prion-like) Amyloid beta (Aβ) in Alzheimer’s.
.

Business Documents

MG cp Summary
  • Alzheimer’s Disease (AD) is largest chronic unmet medical need – Over 5 million patients in North America with full blown Alzheimer’s disease, and a further 10 million in earlier stages of AD; Current medical costs in USA estimated at hundreds of billions of dollars, and expected to triple over next 15 years.
  • ProMIS has multiple, product candidates identified for AD – Precisely targeted against prion strains of Amyloid beta (Aβ), the root cause of Alzheimer’s.
  • Unique science team and experience – Deep understanding of prion forms of proteins, with use of proprietary algorithms for identifying and patenting targets and therapeutics for AD and other neurodegenerative diseases.
  • Breadth of granted and emerging patent estate
    • in ALS, robust patent estate granted worldwide for SOD1 related targets & antibody therapeutics;
    • in AD, provisional patents for misfolded Aβ targets submitted (n=4) or planned (n=2) for submission;
    • proprietary algorithms, patents granted worldwide for ProMISTM, submitted for Collective Coordinates technology.

As its primary objective, the Company focuses on the discovery and development of precision therapeutics and companion diagnostics directed against prion strains of Amyloid beta (Aβ), the root cause of Alzheimer’s.

In Alzheimer’s, ProMIS has identified six distinct epitope targets uniquely associated with the prion forms of Aβ, created murine antibodies against these targets, and on screening has identified multiple product candidates for each of these targets, as announced on June 2, 2016.

We are currently conducting validation studies with cadaveric brain tissue from Alzheimer’s patients in order to select among these product candidates the best to take forward for clinical development. In all cases, our epitope identification allows us to create companion diagnostics, enabling a precision medicine approach to clinical trials and treatment selection for patients.

In ALS, we have three murine antibodies that have been validated as selective for strains of misfolded SOD1. Misfolded, prion-like SOD1 is known to play a key role in the progression of ALS. We are actively seeking a partner, or collaborative partnership for this portfolio, which is covered by an extensive IP estate.

Elliot P Goldstein, MD, President & CEO

Elliot Goldstein brings a unique track record in the clinical, regulatory and commercial development of new pharmaceuticals. Dr. Goldstein began his career with Sandoz Pharmaceuticals in 1980 (now Novartis), a fourteen-year period on drug development in France, Basel, Switzerland Global Headquarters, including as Head of Clinical R&D in the United States. He subsequently held positions as SVP of Strategic Product Development at SmithKline Beecham for 4 yrs. (now GSK), CEO of British Biotech (Oxford, UK) for 4 yrs., Chief Operating Officer and Chief Medical Officer of Maxygen for 7 yrs., and President and CMO of a startup biotech devoted to development of biosimilar monoclonal antibodies

Eugene Williams, MBA, Executive Chairman

Eugene Williams has been a successful biotech and life sciences senior executive, entrepreneur, and innovator for more than 30 years.   His experience spans the spectrum from new start-ups to senior roles in one of the largest and most successful global biotech companies.   His functional area experience includes early and late stage drug development, deal making, biotech commercialization, and healthcare services.   After starting his career in strategy consulting at Bain and company and a spinoff of Bain, he joined Genzyme in the late 1990’s.   He managed the Genzyme therapeutics development portfolio when Genzyme expanded its Orphan Disease business from a single product to multiple products.   His responsibilities included managing the processes by which Genzyme evaluated in-licensing opportunities. As an entrepreneur, he was a founder and director of Adheris, Inc. which became the leading service company addressing patient adherence, and which sold to InVentiv in a deal generating greater than 15x cash on cash returns for investors.   He founded service companies supporting drug development in India and China, and was a founder of DART (now Akashi) an innovative biotech funded by patient foundations focused on Duchenne Muscular Dystrophy.

Neil R. Cashman, MD, Chief Science Officer

Dr. Cashman is a physician and scientist focused on neurodegenerative diseases. His first academic posting was at Montreal Neurological Institute and Hospital of McGill University. From 1998 to 2005, he was the Diener Professor of Neurodegenerative Diseases at the University of Toronto. In 2005, Professor Cashman moved to the University of British Columbia, where he holds the Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases, and serves as the Director of the UBC ALS Centre. He has procured over $50 million in research grant funding from the CIHR, CRC, NCE, NIH, and various corporations for his work involving protein misfolding and prion technologies. He was awarded the Jonas Salk Prize for biomedical research in 2000, and was elected a Fellow of the Canadian Academy of Health Sciences in 2008. He is recognized worldwide as one of the leading research scientists pioneering the emerging fields of prion biology and protein misfolding diseases, in particular Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).

Steven Plotkin, PhD, Chief Physics Officer

Prof. Steven Plotkin is a theoretical and computational biophysicist whose research focuses on protein folding and misfolding in neurodegenerative disease, protein evolution and cellular differentiation, and the molecular mechanisms of cancer. He has been a professor at UBC in the Department of Physics and Astronomy since 2001, where he was appointed as the Canada Research Chair in Theoretical Molecular Biophysics. He was an Alfred P. Sloan Research Fellow in 2005-2006, a Killam Faculty Research Fellow in 2010, and is now an associate member of the Genome Sciences and Technology Program, the Bioinformatics Program, and the Institute for Applied Mathematics at the University of British Columbia. Several of his publications have received the Faculty of 1000 designation, placing them in the top 2% of published articles in biology and medicine.
Plotkin is recognized internationally for his fundamental contributions to the energy landscape theory of protein folding, and presents his research findings in protein misfolding and neurodegeneration, and protein geometry and disorder as an invited speaker at several annual conferences and symposia. His research is currently supported by grants from CIHR, NSERC, APRI, ALS-Canada, and Compute Canada.


EXtatin Inc.

EXtatin Inc.

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
   
Book a Conference Call
Get More Information

EXtatin Inc.

Location: Toronto, Ontario Sector: Life Science  
Add to Shortlist
Express Interest

EXtatin is involved in the research and development of a bio compatible molecule to be introduced topically and sub-dermally in order to facilitate the detachment and disposal of tattoo ink laden cells. The experiments and research are being conducted on live tattooed skin from donors who have undergone surgical excision of the tattooed skin as part of plastic and cosmetic surgery procedures.

Business Documents

MG cp Summary
  • Quality research and Management – Dr. Sheldon Joseph PhD is a qualified cell physiologist with experience cancer research and genetics. He is the principle investigator for the research and development of the company . Frederick Hawa is litigation lawyer (Osgoode) with a BSc (U of T) and MBA (Miami) who has many years of experience in the biotechnology R and D world
  • Immediate Investor interest – Extatin has a core of 50 or so interested individual investors who are prepared to invest $30,000 to $50,000 each should the company fulfill its goals of providing shares which can be traded on the public markets.

EXtatin is involved in the research and development of a bio compatible molecule to be introduced topically and sub-dermally in order to facilitate the detachment and disposal of tattoo ink laden cells. The experiments and research are being conducted on live tattooed skin from donors who have undergone surgical excision of the tattooed skin as part of plastic and cosmetic surgery procedures.

Sheldon Mark Joseph, Ph.D., Co-Founder, Director, Principal Investigator – Sheldon is a creative, resourceful, vibrant, US and UK-trained entrepreneurial scientist. Following his Bachelor of Science (Salutatorian, Summa Cum Laude, Morehouse/HHWI Scholarships, Golden Key Most Outstanding Senior, Phi Beta Kappa, National Deans’ Lists) in Biology (with Honors) at Morehouse College (GA), which included independent research at Lancaster University (Fylde Scholar, UK), he pursued a decorated internship at the Merck Research Laboratories Inc. (NJ) where he earned the title: Most Outstanding Intern. Sheldon continued his award-winning academic career, bypassing the Masters to earn his Ph.D. in Cell Physiology in the Department of Physiology and Biophysics at Case Western Reserve University and the Cleveland Clinic (OH).   While there he earned the Richard O. Recknagel Prize for Best Academic Record and won multiple international research symposia and speaking awards. He then trained as a Post-Doctoral Fellow in Cancer Genetics at the world-renowned Roswell Park Cancer Institute, Center of Excellence (NY). Sheldon is a multi-published scientist and is a sought-after independent Life Sciences Professor and Lecturer at various institutes of higher learning in the Greater Toronto Area, including the University of Toronto’s School of Continuing Studies.   Frederick Simon Hawa, MBA LLB (JD), Co-founder, Business Development Consultant – Frederick is an internationally experienced, entrepreneurial, Toronto-based Barrister who specializes in civil litigation and biotechnology. He earned his Bachelor of Science (with Honors) at the University of Toronto, and continued his successful academic career by earning his MBA (International Business) and LLB (JD) at the University of Miami and York University’s Osgoode Hall.